Try a new search

Format these results:

Searched for:

person:adotap01

in-biosketch:true

Total Results:

38


Barber Knowledge and Recommendations Regarding Pseudofolliculitis Barbae and Acne Keloidalis Nuchae in an Urban Setting [Letter]

Adotama, Prince; Tinker, Daniel; Mitchell, Krystal; Glass, Donald A; Allen, Pamela
PMCID:5817432
PMID: 29049485
ISSN: 2168-6084
CID: 4502662

Association of keloids with systemic medical conditions: a retrospective analysis [Letter]

Adotama, Prince; Rutherford, Audrey; Glass, Donald A
PMID: 26517298
ISSN: 1365-4632
CID: 4502642

Patient satisfaction with different treatment modalities for vitiligo [Letter]

Adotama, Prince; Zapata, Lucio; Currimbhoy, Sharif; Hynan, Linda S; Pandya, Amit G
PMID: 25773415
ISSN: 1097-6787
CID: 4502632

Predictors for the use of systemic therapy in stage IB Mycosis fungoides [Letter]

Rodriguez, Elijah; Needle, Carli D; Martinez, Michael J; Nohria, Ambika; Xing, Yiping; Song, Clara; Betensky, Rebecca; Latkowski, Jo-Ann; Adotama, Prince
BACKGROUND:The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is aprospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) inpatients with newly diagnosed mycosis fungoides (MF). OBJECTIVES/OBJECTIVE:To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB)staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS:In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centresin 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS:The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smallerpercentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariateanalysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA,20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs.T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%,while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improvedsignificantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS:Disease characteristics such as presence of plaques and FMF influence physician treatment choices,and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, futuretreatment guidelines for early-stage MF need to address these issues.
PMID: 38844623
ISSN: 1432-069x
CID: 5665772

Treatment for Central Centrifugal Cicatricial Alopecia - Delphi Consensus Recommendations

Jackson, Tiaranesha; Sow, Yacine; Dinkins, Jewell; Aguh, Crystal; Ayoade, Katherine Omueti; Barbosa, Victoria; Burgess, Cheryl; Callender, Valerie; Cotsarelis, George; Grimes, Pearl; Harvey, Valerie; Kindred, Chesahna; Lester, Jenna; Lo Sicco, Kristen; Mayo, Tiffany; McMichael, Amy; Oboite, Michelle; Ogunleye, Temitayo; Olsen, Elise; Osei-Tutu, Achiamah; Piliang, Melissa; Senna, Maryanne; Shapiro, Jerry; Tosti, Antonella; Frey, Cheri; Adotama, Prince; Taylor, Susan C
BACKGROUND:There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely. OBJECTIVE:To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA. METHODS:We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed. RESULTS:In Round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in Round 2. After the final Round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus. LIMITATIONS/CONCLUSIONS:This study included only English-speaking, US-based dermatologists and did not consider non-pharmacological therapies. CONCLUSION/CONCLUSIONS:Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.
PMID: 38341148
ISSN: 1097-6787
CID: 5635532

Racial Representation in Melanoma YouTube Videos [Editorial]

LaRosa, Sabrina; Vanaria, Robert J; Pham, Liem T; Posner, Kevin M; Buontempo, Michael G; Sicco, Kristen Lo; Adotama, Prince
PMID: 38709687
ISSN: 1545-9616
CID: 5658312

Does the ACGME Prioritize Cosmetic Dermatology Enough?

Dawson, Joshua; Ugonabo, Nkem; McKenzie, Costner; Adotama, Prince
PMID: 38518187
ISSN: 1524-4725
CID: 5640852

Barber Knowledge and Recommendations for Pseudofolliculitis Barbae

Rice, Xavier; Omar, Deega; Goodwin, Brandon P; Adotama, Prince
PMCID:10701658
PMID: 38055241
ISSN: 2168-6084
CID: 5595782

Re-examining melanoma secondary prevention and the role of skin self-examination

Ingrassia, Jenne P; Adotama, Prince; Stein, Jennifer A; Polsky, David
PMID: 37385450
ISSN: 1097-6787
CID: 5540512

Risk of Radiation Dermatitis in Patients With Skin of Color Who Undergo Radiation to the Breast or Chest Wall With and Without Regional Nodal Irradiation

Purswani, Juhi M; Bigham, Zahna; Adotama, Prince; Oh, Cheongeun; Xiao, Julie; Maisonet, Olivier; Teruel, Jose R; Gutierrez, Daniel; Tattersall, Ian W; Perez, Carmen A; Gerber, Naamit K
PURPOSE/OBJECTIVE:Acute radiation dermatitis (ARD) is common after radiation therapy for breast cancer, with data indicating that ARD may disproportionately affect Black or African American (AA) patients. We evaluated the effect of skin of color (SOC) on physician-reported ARD in patients treated with radiation therapy. METHODS AND MATERIALS/METHODS:We identified patients treated with whole breast or chest wall ± regional nodal irradiation or high tangents using 50 Gy in 25 fractions from 2015 to 2018. Baseline skin pigmentation was assessed using the Fitzpatrick scale (I = light/pale white to VI = black/very dark brown) with SOC defined as Fitzpatrick scale IV to VI. We evaluated associations among SOC, physician-reported ARD, late hyperpigmentation, and use of oral and topical treatments for RD using multivariable models. RESULTS:A total of 325 patients met eligibility, of which 40% had SOC (n = 129). On multivariable analysis, Black/AA race and chest wall irradiation had a lower odds of physician-reported grade 2 or 3 ARD (odds ratio [OR], 0.110; 95% confidence interval [CI], 0.030-0.397; P = .001; OR, 0.377; 95% CI, 0.161-0.883; P = .025), whereas skin bolus (OR, 8.029; 95% CI, 3.655-17.635; P = 0) and planning target volume D0.03cc (OR, 1.001; 95% CI, 1.000-1.001; P = .028) were associated with increased odds. On multivariable analysis, SOC (OR, 3.658; 95% CI, 1.236-10.830; P = .019) and skin bolus (OR, 26.786; 95% CI, 4.235-169.432; P = 0) were associated with increased odds of physician-reported late grade 2 or 3 hyperpigmentation. There was less frequent use of topical steroids to treat ARD and more frequent use of oral analgesics in SOC versus non-SOC patients (43% vs 63%, P < .001; 50% vs 38%, P = .05, respectively). CONCLUSIONS:Black/AA patients exhibited lower odds of physician-reported ARD. However, we found higher odds of late hyperpigmentation in SOC patients, independent of self-reported race. These findings suggest that ARD may be underdiagnosed in SOC when using the physician-rated scale despite this late evidence of radiation-induced skin toxicity.
PMID: 37060928
ISSN: 1879-355x
CID: 5502812